Advisors Asset Management Inc. Purchases 7,331 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Advisors Asset Management Inc. lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating) by 26.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,770 shares of the biopharmaceutical company’s stock after purchasing an additional 7,331 shares during the period. Advisors Asset Management Inc.’s holdings in Halozyme Therapeutics were worth $1,530,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in HALO. Victory Capital Management Inc. increased its holdings in Halozyme Therapeutics by 206.7% during the second quarter. Victory Capital Management Inc. now owns 1,790,044 shares of the biopharmaceutical company’s stock worth $78,761,000 after buying an additional 1,206,368 shares during the last quarter. Lisanti Capital Growth LLC purchased a new position in shares of Halozyme Therapeutics in the second quarter worth about $15,441,000. William Blair Investment Management LLC increased its stake in shares of Halozyme Therapeutics by 5.2% in the first quarter. William Blair Investment Management LLC now owns 5,339,891 shares of the biopharmaceutical company’s stock worth $212,955,000 after purchasing an additional 266,226 shares in the last quarter. Loomis Sayles & Co. L P increased its stake in shares of Halozyme Therapeutics by 13.4% in the first quarter. Loomis Sayles & Co. L P now owns 2,185,274 shares of the biopharmaceutical company’s stock worth $87,149,000 after purchasing an additional 257,536 shares in the last quarter. Finally, Covington Capital Management purchased a new position in shares of Halozyme Therapeutics in the second quarter worth about $10,890,000. 91.72% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on HALO. SVB Leerink lifted their target price on shares of Halozyme Therapeutics from $52.00 to $62.00 and gave the stock an “outperform” rating in a research note on Monday. JMP Securities lifted their target price on shares of Halozyme Therapeutics from $60.00 to $62.00 and gave the stock a “market outperform” rating in a research note on Wednesday, November 9th. Morgan Stanley began coverage on shares of Halozyme Therapeutics in a research note on Friday, September 9th. They issued an “overweight” rating and a $50.00 target price for the company. Finally, StockNews.com assumed coverage on shares of Halozyme Therapeutics in a research note on Wednesday, October 12th. They issued a “hold” rating for the company. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $54.57.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $53.91 on Tuesday. The company has a 50 day moving average of $43.68 and a 200 day moving average of $44.39. The stock has a market cap of $7.29 billion, a P/E ratio of 36.18, a P/E/G ratio of 1.00 and a beta of 1.22. Halozyme Therapeutics, Inc. has a 12 month low of $31.36 and a 12 month high of $54.88. The company has a current ratio of 2.72, a quick ratio of 2.23 and a debt-to-equity ratio of 3.91.

Halozyme Therapeutics Company Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Stories

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.